Abbott Laboratories

NYSE ABT

Download Data

Abbott Laboratories Market Capitalization on June 03, 2024: USD 178.96 B

Abbott Laboratories Market Capitalization is USD 178.96 B on June 03, 2024, a 0.07% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.
  • Abbott Laboratories 52-week high Market Capitalization is USD 211.22 B on March 12, 2024, which is 18.03% above the current Market Capitalization.
  • Abbott Laboratories 52-week low Market Capitalization is USD 155.12 B on October 12, 2023, which is -13.32% below the current Market Capitalization.
  • Abbott Laboratories average Market Capitalization for the last 52 weeks is USD 183.48 B.
NYSE: ABT

Abbott Laboratories

CEO Mr. Robert B. Ford
IPO Date Jan. 13, 1978
Location United States
Headquarters 100 Abbott Park Road, North Chicago, IL, United States, 60064-6400
Employees 114,000
Sector Healthcare
Industry Medical devices
Description

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Similar companies

MDT

Medtronic PLC

USD 82.12

0.92%

StockViz Staff

September 8, 2024

Any question? Send us an email